GE
SNDX icon

General Electric’s Syndax Pharmaceuticals SNDX Stock Holding History

General Electric’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-47,945
Closed -$726K – 6
2016
Q3 		$726K Sell
47,945
-5,701
-11% -$75K 0.37% 5
2016
Q2 		$528K Hold
53,646
– – ﹤0.01% 205
2016
Q1 		$715K Buy
+53,646
New +$674K ﹤0.01% 210

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

General Electric's SNDX Position: Q4 2016 in Review

General Electric sold out of Syndax Pharmaceuticals (SNDX) in Q4 2016, closing a stake of 47,945 shares — an estimated $726K sold.

General Electric first reported a position in SNDX in Q1 2016 and held it in 3 quarters. The position peaked at $726K in Q3 2016. 57 funds tracked by Wall St. Rank hold SNDX as of Q4 2016.

  • General Electric reported no remaining Syndax Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • General Electric sold 47,945 Syndax Pharmaceuticals shares in Q4 2016, an estimated $726K.
  • General Electric first reported a position in Syndax Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • General Electric's Syndax Pharmaceuticals position peaked at $726K in Q3 2016.
  • 57 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2016.

Based on General Electric's 13F filing for Q4 2016, filed 13 Feb 2017.